Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Empagliflozin on Functional Capacity in Heart Failure with Preserved Ejection Fraction

NCT05139472 is registered in ClinicalTrials.gov with University of Texas Southwestern Medical Center as lead sponsor.

NCT NCT05139472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05139472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Empagliflozin on Functional Capacity in Heart Failure with Preserved Ejection Fraction
Lead sponsor
University of Texas Southwestern Medical Center
Phase
Phase 4
Overall status
Completed
Start date
November 9, 2021
Completion date
February 19, 2024
Enrollment
8 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, heart failure with preserved ejection fraction, heart failure, diastolic